Trials / Not Yet Recruiting
Not Yet RecruitingNCT07350421
The Effectiveness of Inhaled Salbutamol in the Management of Transient Tachypnea of the Newborn(TTN)
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1 (estimated)
- Sponsor
- Tishreen University · Academic / Other
- Sex
- All
- Age
- 1 Hour – 6 Hours
- Healthy volunteers
- Not accepted
Summary
TTN is the most common respiratory disorder in the perinatal period, causing 40% of cases of respiratory distress after birth. Lung fluid absorption is initiated by beta-adrenergic agonists, such as endogenous steroids and Catecholamine, which increase during labor. Delayed absorption of fluid from the lungs is thought to be the primary mechanism of transient tachypnea of the newborn (TTN). The accumulation of fluid within the lungs impairs gas exchange, leading to increased respiratory effort. Tachypnea develops to compensate for this, and hypoxemia develops due to impaired alveolar ventilation . The main objective of the study: To study the effectiveness of salbutamol in improving signs of respiratory distress according to the modified Downes score during the first 72 hours of life in infants with transient tachypnea of the newborn (TTN). Secondary objectives: Duration of tachypnea (time to resolution of respiratory distress) Reducing the duration of the need for oxygen support Reducing the length of hospital stay
Detailed description
Patients will be divided into two groups: Intervention group B: receives a single dose of inhaled salbutamol at a dose of 0.15 mg/kg mixed with 2 ml of 0.9% normal saline. Control group A: receives 2 ml of 0.9% normal saline. The study population consists of newborns born at Al-Ladhiqiyah University Hospital with a gestational age greater than 35 weeks who show signs of respiratory distress within the first 6 hours of birth.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Salbutamol (Albuterol) | It belongs to a class of medications known as short-acting beta-2 adrenergic agonist. |
| DRUG | Normal Saline | normal saline by inhalation |
Timeline
- Start date
- 2026-01-01
- Primary completion
- 2027-01-01
- Completion
- 2028-03-01
- First posted
- 2026-01-20
- Last updated
- 2026-01-20
Locations
1 site across 1 country: Syria
Source: ClinicalTrials.gov record NCT07350421. Inclusion in this directory is not an endorsement.